News
Business Results Q4 of 2016
Cosmos Holdings Inc. reported strong revenue growth in the fourth quarter of 2016 over the previous quarter. Sales increased from $1,414,000 to $3,070,000 from Q3 2016 to Q4 2016, respectively, an over 110% improvement. The increase was due to organic growth in sales from the Company’s subsidiary Sky Pharm SA. Cosmos Holdings had revenue for the full year ended December 31, 2016, of $6,755,436, versus $533,802 for the full year ended December 31, 2015. During 2016, revenues increased over ...
Cosmos Holdings, Inc. Acquires Decahedron Ltd
CHICAGO, IL - (Marketwired - Feb 14, 2017) - Cosmos Holdings, Inc. ("the Company") (OTCQB: COSM), an international pharmaceutical company, announced today that the Company acquired 100% of the shares of Decahedron Ltd, a privately held company located in Harlow, United Kingdom just north of London. Decahedron Ltd. is a pharmaceutical wholesaler incorporated in the UK in August 2011 and it is audited by the MHRA (Medicines and Healthcare Products Regulatory Agency) under European GDP (Good Distribution Practices). Decahedron is ...
Cosmos Holdings, Inc. Establishes its Advisory Board and Adds Orestes Varvitsiotes as its Initial Member
Cosmos Holdings, Inc., announced that Orestes Varvitsiotes has been appointed as the initial board member of its Advisory Board of Directors. Mr. Varvitsiotes is currently working with Aegis Capital Corp. in New York. He is a wealth management professional with more than 25 years of experience in the capital markets. His experience extends in various fields of the financial industry such as financial consulting, portfolio management, trading and capital raising. Cosmos Holdings CEO Gregory Siokas commented, "As the company grows we ...
Cosmos Holdings, Inc. Adds John J. Hoidas to Its Board of Directors
Cosmos Holdings, Inc, announced that John J. Hoidas has been appointed to the Company's board of directors, expanding the board to four members. Mr. Hoidas is currently a senior vice president with Uhlmann Price Securities in Chicago. He is a wealth management professional with extensive experience in the capital markets. He has raised capital for late stage pre-IPO companies such as Organovo (ONVO), Invivo Therapeutics (NVIV) and Matinas BioPharma (MTNB) to name a few. Cosmos Holdings CEO Gregory Siokas commented, "I am ...
Business Results Q3 of 2016
Sales and operating margins continue to improve from Q2 to Q3 of FY 2016. Strong revenue growth reported in the third quarter of FY 2016 over the previous quarter. Sales increased from $956k to $1,414k from Q2 2016 to Q3 2016 respectively, an over 47% increase. The increase was due to organic growth in the sales from our subsidiary Sky Pharm SA. Gross operating margins also improved from Q2 2016 to Q3 2016. Cosmos Holdings was successful in raising ...
Photo
Steve Carr Managing Director
Cosmos-logo